Search results
Hope For Long COVID As Patients Show Immune System Improvements After 2 Years
IFLScience· 5 days agoMarkers of immune dysfunction in a cohort of people with long COVID had largely resolved after two...
COVID-19 booster immunity lasts much longer than primary series alone, study shows
Medical Xpress· 5 days agoThe study's authors—York Post Doctoral researchers Chapin Korosec and David Dick, Applied Mathematics Professor Iain Moyles and Professor James Watmough with the University of New Brunswick—used ...
Advancing RSV surveillance and disease burden as part of an expanded Global Influenza Surveillance...
World Health Organization· 5 days agoRespiratory Syncytial Virus (RSV) is a significant cause of acute lower respiratory infections and a leading cause of hospitalization in infants and young children. The World Health Organization ...
Xencor (NASDAQ:XNCR) Shares Down 4.5% on Analyst Downgrade
ETF DAILY NEWS· 5 days agoXencor, Inc. (NASDAQ:XNCR – Get Free Report)’s stock price was down 4.5% during trading on Tuesday after BTIG Research lowered their price target on the stock from $56.00 to $38.00. BTIG Research ...
How Vir found the one: CEO Marianne De Backer
FierceBiotech· 4 days agoVir Biotechnology conducted a worldwide search to find the perfect CEO. In the end, the board picked Bayer’s Marianne De Backer, Ph.D., because of her...
Texas Biomed researching vaccines and treatments for highly pathogenic avian influenza
WFRV 5 Green Bay· 5 days agoResearchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains ...
Texas Biomed researching vaccines and treatments for highly pathogenic avian influenza
The Longview News-Journal· 5 days agoResearchers at Texas Biomedical Research Institute (Texas Biomed) are studying potential vaccines, antivirals and antibodies against highly pathogenic avian influenza, including H5N1 strains ...
Xencor (NASDAQ:XNCR) Price Target Cut to $38.00
ETF DAILY NEWS· 5 days agoXencor (NASDAQ:XNCR – Get Free Report) had its target price lowered by analysts at BTIG Research from $56.00 to $38.00 in a research report issued to clients and investors on Tuesday, MarketBeat.com ...
